Q4 2024. Management View. CEO Kristin Peck highlighted Zoetis delivered an excellent 2024, achieving double-digit operational revenu ...

Welcome to the fourth-quarter and full-year 2024 financial results conference call and webcast for Zoetis. Hosting the call ...

Q4 2024 Earnings Call Transcript February 13, 2025 Zoetis Inc. beats earnings expectations. Reported EPS is $1.4, ...

Zoetis exceeded market expectations in Q4 2024, with impressive financial performance despite challenges in specific segments ...

Zoetis Inc (ZTS) reports robust financial performance with significant growth in companion animal products and strategic ...

ZTS delivered fourth-quarter 2024 adjusted earnings (excluding one-time items) of $1.40 per share, which surpassed the Zacks ...

Coming up: In 2025, Zoetis is set to face more direct competition for some its flagship therapies, including Apoquel and Simparica Trio. It's not clear that rival Elanco's new entrants (Zenrelia ...

During the fourth quarter, Zoetis observed major revenue growth in companion animal products, marking an 8% increase. This growth is attributed to notable products such as Simparica Trio ...

as well as Zoetis’ parasiticide products, such as Simparica and the Simparica Trio. Livestock product sales were flat year over year on a reported basis and grew 6% operationally to $477 million.

For the fourth quarter, Zoetis saw revenue increase 5% year-over-year, or 6% on an operational basis. The company's U.S. segment revenue rose 4% to $1.3 billion, driven by strong sales of companion ...